The 2024 Nobel Prize in Physiology or Medicine jointly to Victor Ambros and Gary Ruvkun
7.10.2024 12:15:58 CEST | Karolinska Institutet - English | Press Release
The Nobel Assembly at Karolinska Institutet has today decided to award the 2024 Nobel Prize in Physiology or Medicine jointly to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation.
This year’s Nobel Prize honors two scientists for their discovery of a fundamental principle governing how gene activity is regulated.
The information stored within our chromosomes can be likened to an instruction manual for all cells in our body. Every cell contains the same chromosomes, so every cell contains exactly the same set of genes and exactly the same set of instructions. Yet, different cell types, such as muscle and nerve cells, have very distinct characteristics. How do these differences arise? The answer lies in gene regulation, which allows each cell to select only the relevant instructions. This ensures that only the correct set of genes is active in each cell type.
Victor Ambros and Gary Ruvkun were interested in how different cell types develop. They discovered microRNA, a new class of tiny RNA molecules that play a crucial role in gene regulation. Their groundbreaking discovery revealed a completely new principle of gene regulation that turned out to be essential for multicellular organisms, including humans. It is now known that the human genome codes for over one thousand microRNAs. Their surprising discovery revealed an entirely new dimension to gene regulation. MicroRNAs are proving to be fundamentally important for how organisms develop and function.
Tiny RNAs with profound physiological importance
Gene regulation by microRNA, first revealed by Ambros and Ruvkun, has been at work for hundreds of millions of years. This mechanism has enabled the evolution of increasingly complex organisms. We know from genetic research that cells and tissues do not develop normally without microRNAs. Abnormal regulation by microRNA can contribute to cancer, and mutations in genes coding for microRNAs have been found in humans, causing conditions such as congenital hearing loss, eye and skeletal disorders. Mutations in one of the proteins required for microRNA production result in the DICER1 syndrome, a rare but severe syndrome linked to cancer in various organs and tissues.
Ambros and Ruvkun’s seminal discovery in the small worm C. elegans was unexpected, and revealed a new dimension to gene regulation, essential for all complex life forms.
Nobel Prize laureates in Physiology or Medicine 2024
Victor Ambros was born in 1953 in Hanover, New Hampshire, USA. He received his PhD from Massachusetts Institute of Technology (MIT), Cambridge, MA, in 1979 where he also did postdoctoral research 1979-1985. He became a Principal Investigator at Harvard University, Cambridge, MA in 1985. He was Professor at Dartmouth Medical School from 1992-2007 and he is now Silverman Professor of Natural Science at the University of Massachusetts Medical School, Worcester, MA.
Gary Ruvkun was born in Berkeley, California, USA in 1952. He received his PhD from Harvard University in 1982. He was a postdoctoral fellow at Massachusetts Institute of Technology (MIT), Cambridge, MA, 1982-1985. He became a Principal Investigator at Massachusetts General Hospital and Harvard Medical School in 1985, where he is now Professor of Genetics.
Keywords
Contacts
Ann-Mari DumanskiThe Nobel Assembly at Karolinska Institutet
Tel:+46-8 524 878 00nobelforum@nobelprizemedicine.orgPernilla WitteThe Nobel Assembly at Karolinska Institutet
Tel:+46-8 524 861 07nobelforum@nobelprizemedicine.orgAbout The Nobel Assembly
The Nobel Assembly, consisting of 50 professors at Karolinska Institutet, awards the Nobel Prize in Physiology or Medicine. Its Nobel Committee evaluates the nominations. Since 1901 the Nobel Prize has been awarded to scientists who have made the most important discoveries for the benefit of humankind.
Subscribe to releases from Karolinska Institutet - English
Subscribe to all the latest releases from Karolinska Institutet - English by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Karolinska Institutet - English
Controlled peanut intake may reduce allergies in toddlers7.5.2026 00:30:00 CEST | Press Release
Researchers at Karolinska Institutet have successfully treated children aged 1–3 years with peanut allergies. The children slowly became accustomed to eating peanuts by consuming small amounts of them daily, which were gradually increased over time. The results are presented in The Lancet Regional Health – Europe.
Karolinska Institutet receives half-billion donation for dementia research25.3.2026 11:00:39 CET | Press Release
Entrepreneur and inventor Leif Lundblad (1938–2025) has bequeathed SEK 538 million to Karolinska Institutet, the largest donation ever to have been made to a Swedish university in modern times. Much of the sum will go towards research on dementia diseases.
HPV vaccine provides long-term protection against cervical cancer26.2.2026 00:30:00 CET | Press Release
HPV vaccination reduces the risk of cervical cancer for at least 18 years, according to a new study from Karolinska Institutet published in The BMJ. There were no signs of waning protection over time.
Blood test reveals risk of multimorbidity7.1.2026 10:00:00 CET | Press Release
A small set of common blood biomarkers predicts which older adults will develop specific combinations of chronic diseases – and how quickly, a new study from Karolinska Institutet published in Nature Medicine reports.
Using social media may impair children’s attention8.12.2025 06:01:00 CET | Press Release
Children who spend a significant amount of time on social media tend to experience a gradual decline in their ability to concentrate. This is according to a comprehensive study from Karolinska Institutet, published in Pediatrics Open Science, where researchers followed more than 8,000 children from around age 10 through age 14.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom